In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on VistaGen Therapeutics (VTGN – Research Report). The company’s shares closed yesterday at $0.16.
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Atossa Therapeutics, and Capricor Therapeutics. According to TipRanks, McCarthy has an average return of -37.6% and a 16.55% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for VistaGen Therapeutics with a $0.23 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.26 and a one-year low of $0.14. Currently, VistaGen Therapeutics has an average volume of 9.58M.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is neutral on the stock. Most recently, in May 2022, Shawn Singh, the CEO of VTGN bought 100,000.00 shares for a total of $100,000.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Read More on VTGN:
